Explore /
Poster
/ Clonal hematopoiesis of indeterminate potential (CHIP), treatment outcomes and adverse events in gastrointestinal cancers: A pooled analysis of clinical trial and real-world data.

Clonal hematopoiesis of indeterminate potential (CHIP), treatment outcomes and adverse events in gastrointestinal cancers: A pooled analysis of clinical trial and real-world data.

Authors

Tharani Krishnan

BC Cancer - Vancouver, Vancouver, BC, Canada

Tharani Krishnan , Joao Paulo Solar Vasconcelos , Emma Titmuss , James Thomas Topham , David F. Schaeffer , Howard J Lim , Cheryl Ho , Sharlene Gill , Hagen Fritz Kennecke , Derek J. Jonker , Eric Xueyu Chen , Daniel John Renouf , Christopher J. O'Callaghan , Jonathan M. Loree , Aly Karsan

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Colorectal Cancer,Anal Cancer

Sub Track

Tumor Biology, Biomarkers, and Pathology

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr 169)

DOI

10.1200/JCO.2024.42.3_suppl.169

Abstract #

169

Poster Bd #

K17

Abstract Disclosures

Similar Posters

Poster

2023 ASCO Annual Meeting

Clonal hematopoiesis in the phase 3 Alliance A031201 trial of metastatic castration resistant prostate cancer (mCRPC) treated with androgen receptor (AR)-targeted therapies.

First Author: Jeffrey Lee Jensen

Poster

2022 ASCO Annual Meeting

$Phase 2 study of ASTX727 (cedazuridine/decitabine) plus venetoclax (ven) in patients with relapsed/refractory acute myeloid leukemia (AML) or previously untreated, elderly patients (pts) unfit for chemotherapy.$